District Court in 9th Circuit Finds That Heightened Pleading Standard Applies to All Prongs of False Patent Marking Claim

October 11, 2024

Reading Time : 2 min

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

After being sued for infringing two patents directed to magnetic building tiles, defendant filed counterclaims alleging false patent marking under 35 U.S.C. § 292(a). Defendant alleged that plaintiff had marked its products with the now-abandoned U.S. patent application, No. 17/140,367 (“the ’367 application”) and that the statement “patent pending” on its website was false because the ’367 application was no longer alive.

Plaintiff filed a motion to dismiss the counterclaim. To survive a motion to dismiss under the Iqbal/Twombly standard, a counterclaim “must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” The allegations cannot be merely conclusory or based on unreasonable inferences. Under Rule 9(b), when alleging fraud, a party “must state with particularity the circumstances constituting fraud.”

 In the case of a false patent marking claim, defendant must plead sufficient facts to show that plaintiff (1) marked an unpatented article and (2) intended to deceive the public by doing so. This requires an intent to deceive the public and sounds in fraud, in accordance with the Rule 9(b) pleading requirements. To show an intent to deceive, there must be an objective indication to reasonably infer that the party was aware that the patent expired, such that a general allegation that they knew or should have known is insufficient.

For a false patent marking claim, defendant must also show that the defendant (3) suffered a competitive injury as a result of a violation of the marking statute. The court recognized that there was a split among district courts as to whether the heightened Rule 9(b) requirements applied to the competitive injury requirement, with some courts only applying the standard to the first two elements.

The court concluded that defendant had stated with particularity that plaintiff used patents and patent applications to advertise its products to consumers, meeting the first element, but did not find that defendant alleged facts from which the court could make a reasonable inference that there was an intent to deceive.

As to the third element, the court recognized the split in authority, but found that 9thCircuit jurisprudence was clear that the Rule 9(b) pleading requirement applied to false patent marking claims in their entirety. Similarly, although the Federal Circuit had not spoken on the issue, precedent from that tribunal further supported this conclusion. Therefore, the court also applied Rule 9(b)’s heightened pleading standard to the third element, competitive injury. However, regardless of whether the heightened pleading standard applied, the court concluded that defendant did not allege sufficient facts to show competitive injury.

The court granted plaintiff’s motion to dismiss on the ground that defendant failed to sufficiently plead two of the three prongs required for false patent marking: intent to deceive and competitive injury.

Practice Tip: In at least the Central District of California, a party alleging a false patent marking claim should recognize that the entire claim is subject to the heightened pleading standard of Rule 9(b), and should plead accordingly. Aside from well-pleaded factual allegations showing that plaintiff marked an unpatented and article and intended to deceive, this also includes alleging particular instances (avoiding conclusory or speculative allegations without factual support) sufficient to show competitive injury caused by the other party.

Squaregles LLC v. Laltitude LLC, No. 2:23-cv-09751-CBM-(BFMx) (C.D. Cal. July 2, 2024).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.